계명대학교 의학도서관 Repository

Metformin and Gastrointestinal Cancer Development in Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea

Metadata Downloads
Author(s)
Ji Hong YouSun Ok SongMin Jin KangYoon Young ChoSun Wook KimSung Hwan SuhSujin LeeYong-ho LeeByung-Wan Lee
Keimyung Author(s)
You, Ji Hong
Department
Dept. of Internal Medicine (내과학)
Journal Title
Clinical and Translational Gastroenterology
Issued Date
2020
Volume
11
Issue
11
Abstract
INTRODUCTION:
Clinical studies have produced conflicting results on the effects of metformin on gastrointestinal cancer development. We aimed to investigate the association between metformin use and stomach, colon, liver, and pancreatic cancer development among patients with newly diagnosed, drug-naïve type 2 diabetes.

METHODS:
This retrospective study evaluated propensity score-matched patients with newly diagnosed type 2 diabetes from the Korean National Health Insurance Service database. Metformin users were categorized into tertiles according to the cumulative dose or duration of metformin treatment, and the risks of gastrointestinal cancers were compared.

RESULTS:
Metformin users had reduced risks of developing stomach cancer (hazard ratio [HR]: 0.841, 95% confidence interval [CI]: 0.797–0.887), colon cancer (HR: 0.865, 95% CI: 0.822–0.91), and liver cancer (HR: 0.709, 95% CI: 0.675–0.746; P < 0.001). However, metformin users did not have a reduced overall risk of pancreatic cancer (HR: 1.335, 95% CI: 1.209–1.475; P < 0.001). The risks tended to decrease at higher cumulative doses and durations of metformin use, with significantly reduced risks of all 4 cancers at the highest cumulative dose (≥1,200,000 mg) and the longest duration (≥2,000 days) of metformin use.

DISCUSSION:
This population-based data suggest that metformin could be associated with reductions in the risks of stomach, colon, and liver cancers, as well a reduced risk of pancreatic cancer in some subgroups. Metformin has benefit as a first-line treatment for type 2 diabetes mellitus. A further role in cancer risk reduction could be studied in controlled trials.
Keimyung Author(s)(Kor)
유지홍
Publisher
School of Medicine (의과대학)
Citation
Ji Hong You et al. (2020). Metformin and Gastrointestinal Cancer Development in Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea. Clinical and Translational Gastroenterology, 11(11), e00254. doi: 10.14309/ctg.0000000000000254
Type
Article
ISSN
2155-384X
Source
https://journals.lww.com/ctg/Fulltext/2020/11000/Metformin_and_Gastrointestinal_Cancer_Development.2.aspx
DOI
10.14309/ctg.0000000000000254
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43437
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.